Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AbelZeta Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06935474
- Locations
- 🇺🇸
AbelZeta, Inc., Rockville, Maryland, United States
C-TIL051 in Non-Small Cell Lung Cancer
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AbelZeta, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05676749
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Ochsner MD Anderson Cancer Center, New Orleans, Louisiana, United States
🇺🇸Duke Center for Cancer Immunotherapy, Raleigh, North Carolina, United States
News
Johnson & Johnson's Dual-Targeting CAR-T Therapy Achieves 80% Complete Response Rate in Lymphoma Trial
Johnson & Johnson's investigational dual-targeting CAR-T therapy JNJ-4496 demonstrated 75-80% complete response rates in patients with relapsed or refractory large B-cell lymphoma at the recommended Phase 2 dose.